The European Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”.
The patent protects the Company’s technology platform NLAB Spiro™ by giving exclusivity on the stated method for producing particles loaded with active pharmaceutical ingredients for lung delivery, among others.
” This patent is a milestone for Nanologica, and it is pleasing that we now have patent protection in Europe for our inhalation platform. We are still at an early stage, but the platform shows great potential and we continue our development work internally as well as in collaboration with external partners”, says Adam Feiler, CTO Nanologica.
NLAB Spiro™ is a scalable drug delivery platform consisting of micrometre sized spherical silica particles, fully soluble in simulated lung fluid. Nanologica has started the toxicological study program for NLAB Spiro™, with short-term as well as long-term studies to validate the platform’s safety profile.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.
About NLAB Spiro™
NLAB Spiro™ is Nanologica’s technology platform for inhalation. The platform is constituted of biologically degradable nanoporous silica particles that can be loaded with APIs inside the pores of the particles. The particles are spherical, non-aggregating and appears as a free-flowing powder. The aerodynamical properties are tailored for inhalation and the particle size ranges between 2 µm and 5 µm, which means they can reach a desired part of the lung – the smaller the particle, the deeper into the lung it can reach. Once reaching the lung, the API is released giving a treatment effect locally. NLAB Spiro™ can improve solubility and/or the bioavailability of an API, protect an API from degradation, provide a controlled release profile, and enable local treatment with lowered systemic effects, which creates new treatment options for lung diseases.